Bold Plans Pivotal GI Cancer Studies After Phase II Success
With First-In-Class Approach
Executive Summary
The private Canadian biotech is advancing a first-in-class GRP78 inhibitor into Phase III studies in gastrointestinal cancers after interim Phase II data suggested potential to improve upon on standard-of-care efficacy.